{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-014079","form_type":"8-K","ticker":"VYCO","cik":"0001424768","company_name":"VYCOR MEDICAL INC","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.050379+00:00","generated_at":"2026-05-15T08:08:10.108725+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vycor Medical annual revenue up 17% to $1.86M; operating profit swings to positive","bullets":["Total revenue $1,863,400 (+17% YoY); Vycor Medical division $1,796,070 (+18%), driven by international growth.","GAAP operating profit of $33,900 vs loss of $9,145 in 2024; non-GAAP operating profit $145,881 (+79%).","Gross margin 83% vs 89% in 2024 due to higher costs and international sales mix.","NovaVision revenue $67,330 (-8% YoY); study validated NeuroEyeCoach for home use.","Seven new peer-reviewed VBAS studies published in 2025; total clinical papers reach 50."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-014079","json":"https://secwatch.observer/filing/0001493152-26-014079.json","markdown":"https://secwatch.observer/filing/0001493152-26-014079.md","text":"https://secwatch.observer/filing/0001493152-26-014079.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1424768/000149315226014079/0001493152-26-014079-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1424768/000149315226014079/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:08:10.108725+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"47662fad6e1b77f4f9ae073e367de018d92fa08f","claim":"VYCOR MEDICAL INC reported financial results for the year ended December 31, 2025.","evidence_excerpt":"On March 31, 2026, we issued a press release regarding our financial results for the year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1424768/000149315226014079/0001493152-26-014079-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}